HUTCHMED (HCM) Competitors

GBX 324.97
+0.97 (+0.30%)
(As of 03:27 AM ET)

HCM vs. INDV, HIK, GNS, SPI, ONT, CRW, CTEC, SN, BMK, and BXP

Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Indivior (INDV), Hikma Pharmaceuticals (HIK), Genus (GNS), Spire Healthcare Group (SPI), Oxford Nanopore Technologies (ONT), Craneware (CRW), ConvaTec Group (CTEC), Smith & Nephew (SN), Benchmark (BMK), and Beximco Pharmaceuticals (BXP). These companies are all part of the "medical" sector.

HUTCHMED vs.

HUTCHMED (LON:HCM) and Indivior (LON:INDV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, community ranking, media sentiment and valuation.

HUTCHMED has a net margin of 12.03% compared to Indivior's net margin of 0.44%. HUTCHMED's return on equity of 14.65% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED12.03% 14.65% 0.99%
Indivior 0.44%12.20%9.94%

Indivior received 360 more outperform votes than HUTCHMED when rated by MarketBeat users. Likewise, 80.35% of users gave Indivior an outperform vote while only 78.40% of users gave HUTCHMED an outperform vote.

CompanyUnderperformOutperform
HUTCHMEDOutperform Votes
196
78.40%
Underperform Votes
54
21.60%
IndiviorOutperform Votes
556
80.35%
Underperform Votes
136
19.65%

Indivior has a consensus price target of GBX 2,515, indicating a potential upside of 87.83%. Given Indivior's higher probable upside, analysts plainly believe Indivior is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Indivior
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

HUTCHMED has higher earnings, but lower revenue than Indivior. HUTCHMED is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£838M3.31£100.78M£0.093,610.80
Indivior£1.12B1.62£5M£0.0344,633.33

34.3% of HUTCHMED shares are held by institutional investors. Comparatively, 83.7% of Indivior shares are held by institutional investors. 42.9% of HUTCHMED shares are held by company insiders. Comparatively, 3.3% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

HUTCHMED has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500.

In the previous week, HUTCHMED had 2 more articles in the media than Indivior. MarketBeat recorded 2 mentions for HUTCHMED and 0 mentions for Indivior. HUTCHMED's average media sentiment score of 0.17 beat Indivior's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media.

Company Overall Sentiment
HUTCHMED Neutral
Indivior Neutral

Summary

HUTCHMED beats Indivior on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCM vs. The Competition

MetricHUTCHMEDDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£2.77B£1.21B£5.02B£1.44B
Dividend Yield4.63%2.99%44.82%11.84%
P/E Ratio3,610.80438.41162.171,675.61
Price / Sales3.318,532.202,364.43309,976.42
Price / Cash2.499.9434.3732.84
Price / Book3.786.865.452.71
Net Income£100.78M£143.33M£100.67M£174.61M
7 Day Performance-7.15%1,722.23%117.54%1.10%
1 Month Performance20.36%1,854.64%124.74%4.89%
1 Year Performance57.75%2,041.32%134.79%10.24%

HUTCHMED Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INDV
Indivior
0 of 5 stars
GBX 1,430.39
+0.6%
GBX 2,515
+75.8%
-9.8%£1.94B£1.12B47,679.601,000
HIK
Hikma Pharmaceuticals
0.8382 of 5 stars
GBX 1,970
+0.7%
GBX 2,068.75
+5.0%
+8.3%£4.37B£2.88B2,897.069,100High Trading Volume
GNS
Genus
0 of 5 stars
GBX 1,882
-0.2%
GBX 4,500
+139.1%
-25.8%£1.24B£673.10M3,690.203,500Gap Down
SPI
Spire Healthcare Group
0.7738 of 5 stars
GBX 252
+0.6%
GBX 302.25
+19.9%
+8.2%£1.02B£1.36B3,600.0012,787
ONT
Oxford Nanopore Technologies
2.3955 of 5 stars
GBX 112.80
+1.5%
GBX 303.75
+169.3%
-56.2%£973.00M£169.67M-593.681,238Positive News
CRW
Craneware
1.1703 of 5 stars
GBX 2,390
+0.4%
GBX 2,600
+8.8%
+45.1%£844.39M£180.56M11,380.95734
CTEC
ConvaTec Group
1.0324 of 5 stars
GBX 260.40
-0.2%
GBX 307.17
+18.0%
+11.1%£5.34B£2.14B5,208.0010,136
SN
Smith & Nephew
2.1447 of 5 stars
GBX 997.80
+0.1%
GBX 1,346.20
+34.9%
-21.1%£8.72B£5.55B4,157.5018,452High Trading Volume
BMK
Benchmark
0 of 5 stars
GBX 45.81
+1.8%
N/A+11.9%£338.75M£155.53M-1,526.83823
BXP
Beximco Pharmaceuticals
0 of 5 stars
GBX 37.50
-1.3%
N/A+3.8%£167.29M£41.65B468.755,700Gap Down

Related Companies and Tools

This page (LON:HCM) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners